Genmab A (GMAB) Current Deferred Revenue (2020 - 2025)
Genmab A (GMAB) posted Current Deferred Revenue of $24.0 million for Q4 2025, up 700.0% on a QoQ basis from $3.0 million in Q4 2024, and up 700.0% year-over-year from $3.0 million in Q4 2024.
Genmab A (GMAB) Current Deferred Revenue (2020 - 2025) Analysis & Trends
Genmab A's Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $24.0 million for Q4 2025.
- Quarterly Current Deferred Revenue rose 700.0% year-over-year to $24.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.0 million (up 700.0% YoY) and the FY2025 annual result came in at $24.0 million, up 700.0% from the prior year.
- Current Deferred Revenue was $24.0 million for Q4 2025 at Genmab A, up from $3.0 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $24.0 million in Q4 2025 and bottomed at $3.0 million in Q4 2024.
- A 3-year average of $10.7 million and a median of $5.0 million in 2023 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue tumbled 40.0% — and 2025, when it jumped 700.0%.
- Genmab A's Current Deferred Revenue stood at $5.0 million in 2023, then tumbled by 40.0% to $3.0 million in 2024, then soared by 700.0% to $24.0 million in 2025.
- Business Quant data shows GMAB's Current Deferred Revenue at $24.0 million in Q4 2025, $3.0 million in Q4 2024, and $5.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24.00 Mn |
| Dec 31, 2024 | 3.00 Mn |
| Dec 31, 2023 | 5.00 Mn |
| Sep 30, 2020 | 487.00 |